Objectives
- Research of proteic biomarkers specific of pathological states within the framework of clinical studies
- Development and validation of standard operational procedures for the purification and the analysis of sub proteom and/or peptidom from biological fluids
- Obtaining quality controls necessary and essential for the validation of the clinical proteomic studies
- Development of new methods to gain in sensitivity in adequacy with the constraints of clinical studies
- Highlight of proteomic biomarkers with mass spectrometry starting from complex proteic mixtures (fluid biological, cellular extracts…)
partners
- CLCC JF Leclerc
- Cancéropole Grand Est
- INCa
- EFS-BFC
work completed
- Creation of a quality control and production of 3000 identical samples of plasma conserved at -296°C
- Validation of standard operational procedures on robot TECAN MCA in format head of 96 needles
- Development and validation of new procedures of treatment of the samples (fragmentation, déplétion…)
- Procedures and quality controls applied to the analysis by mass spectrometry of the MALDI-TOF type
results
- Capacity for treatment of 96 samples in parallel
- Gain in reproducibility intra and inter experiments
- Traceability of the whole analytical chain
- Gain in sensitivity for the research of biomarkers
-
Availability of a quality control tool (CQI):
- Measure and controls experimental reproducibility
- Validation of new procedures
Repercussions by sectors of application
-
Basic research :
- Comparative proteomic study with high throughput
- Highlight of new signalisation path
-
Clinical research :
- Large scale proteomic study (> to 500 samples) for the research of biomarkers
- Optimization of the processes of treatment and analysis of the samples
- Identification of new proteic markers
Keywords
- Nanobiotechnologies
- Sensors
- Biochips
- Microtechnologies
Contacts
- Patrick Ducoroy, patrick.ducoroy[at]clipproteomic.fr
- Wilfrid Boireau, wilfrid.boireau[at]clipproteomic.fr
